Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 75.9% from a year ago
Cash & equivalents stood at $22.19M at the end of Q1 FY2026, down 75.9% from a year earlier and down 51.2% from the prior quarter. Over 3 fiscal years it compounded at +10.5% a year.
Context
- Cash & equivalents amounted to 11.0% of total assets at the end of Q1 FY2026, down 15.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -75.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 45.45M USD
- Year-over-year change
- -36.2%
- 4-year CAGR
- -3.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.45M | -36.2% |
| FY2024 | 2024-12-31 | 71.19M | +12.6% |
| FY2023 | 2023-12-31 | 63.23M | +87.7% |
| FY2022 | 2022-12-31 | 33.69M | -34.8% |
| FY2021 | 2021-12-31 | 51.67M | — |
Cash & Equivalents vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's Mar 2026 cash & equivalents of $22.19M is the 8th highest of the 10 companies compared; the peer median is $50.72M.
- Its year-over-year change of -75.9% is the 9th highest of 10, against a peer median of -30.6%.
- Cash & equivalents amounts to 11.0% of total assets for PLRX, versus a peer median of 30.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.06M | +345.0% | -33.6% | 41.7% | |
| Mar 2026 | $73.68M | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $63.17M | +50.0% | +18.3% | 63.6% | |
| Mar 2026 | $50.72M | +42.8% | +99.1% | 95.2% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $34.79M | -84.7% | -1.3% | 27.3% |
| Mar 2026 | $31.93M | -23.8% | -5.8% | 12.6% | |
| Mar 2026 | $22.19M | -75.9% | +10.5% | 11.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M | -31.1% | -36.1% | 19.8% |
| Mar 2026 | $5.94M | -39.6% | -34.3% | 27.4% | |
| Peer median (excluding PLRX) | $50.72M | -30.6% | -5.8% | 30.4% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 51.67M | 33.69M | 63.23M | 71.19M | 45.45M |
| Short-term Investments | 148.93M | 297.5M | 431.01M | 284.54M | 145.5M |
| Net Receivables | 2.47M | 3.14M | 3M | 2.3M | 823K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 156K | 173K | 1.27M | 163K | 1.13M |
| Total Current Assets | 209.44M | 340.31M | 505.5M | 362.26M | 196.45M |
| Property, Plant & Equipment (Net) | 10.94M | 9.91M | 4.78M | 32.77M | 25.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 838K | 394K | 1.87M | 1.92M | 3.77M |
| Total Non-current Assets | 11.77M | 10.3M | 6.65M | 34.69M | 28.78M |
| Total Assets | 221.22M | 350.61M | 512.15M | 396.95M | 225.23M |
| Account Payables | 2.97M | 1.58M | 4.53M | 5.96M | 480K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.22M | 7.2M | 9.04M | 11.15M | 8.3M |
| Total Current Liabilities | 16.83M | 23.91M | 28.52M | 33.22M | 16.37M |
| Long-term Debt | 0 | 9.93M | 10.05M | 30.21M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.33M | 13.36M | 10.05M | 59.65M | 27.66M |
| Total Liabilities | 22.16M | 37.27M | 38.58M | 92.87M | 44.02M |
| Common Stock | 3K | 5K | 6K | 6K | 6K |
| Retained Earnings | (215.09M) | (338.41M) | (499.75M) | (710.05M) | (859.4M) |
| Accumulated OCI | (201K) | (1.96M) | 345K | 321K | (15K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 199.06M | 313.34M | 473.58M | 304.08M | 181.21M |
| Total Debt | 7.19M | 15.82M | 11.37M | 60.19M | 29.11M |
| Net Debt | (44.47M) | (17.87M) | (51.86M) | (11M) | (16.34M) |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.